Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Comment

How should research be priced in a post-Mifid II world?

Being Mifid II-ready has become a competitive advantage which will set firms apart, according to Brij Malkan from BCA research.

Can refundable performance fees work?

Orbis Investments is the traditional percentage of assets-based fees but it may be ttoo early to tell if the new structure is working

The trials and tribulations of living through M&A

Plenty is written about the impact of the frequent merger and acquisition activity in wealth management on clients, but what about the staff involved?

Diary of a digital investor: Nutmeg's first investment review

In the second part of the series, I find that I have three different risk profiles assigned by four robo-advisers and take a look at how Nutmeg invested my money.

Clientology: City hotshots - tough and relaxed

When it comes to investing their cash, City workers are not as demanding as you might expect

Mifid II demands a mindset change in delivering best execution

Mifid II presents a golden opportunity for asset managers, writes Alex Kerry, head of Winterflood Business Services

Bitcoin: Should you invest in the crypto-currency?

So what is the chance the technology will begin to be adopted by the City?

ETF worries: capacity or liquidity?

The problem with capacity is you may get too large for the market; with liquidity that the market can move against you

Diary of a digital investor: on a journey with four robos

We decided to test out four online wealth managers and see what all the fuss is about.

Can 'emboldened' Labour form a minority government?

The Labour party had a great night yesterday but still failed to win a majority, making this the third election it has lost.

Investment Trust video
Play IBT's Craig on the Trump impact for biotech

IBT's Craig on the Trump impact for biotech

Ailsa Craig of the International Biotechnology trust highlights the M&A activity seen in the biotechnology sector this year.

Comment